Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 108, Issue -, Pages 663-669Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2018.09.071
Keywords
Icariin; Mesenchymal stem cell; Stroke; Cerebral ischemia; BDNF; VEGF; ERK1/2; PI3K; Angiogenesis; Neurogenesis
Funding
- TCM Administration Bureau of Zhejiang Province [2014ZA018]
- Science and Technology Project of Zhejiang Education Department of China [Y201636956]
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) are one promising candidate for regenerative therapy of ischaemic stroke through transdifferetiation and paracrine actions. Icariin (ICA) has shown great potential in improving cell activity and VEGF, BDNF secretion in vitro. Whether they will synergistically improve therapy effect on cerebral ischemia is unknown. In this study, male SD rats were subjected to transient middle cerebral artery occlusion (MCAO) followed by reperfusion and ICA/MSC treatment. Results showed that ICA and MSCs combined treatment greatly reduced brain infarction volume, improved neurologic deficits of motor and somatosensory function and neurobehavioral outcomes. The combined therapy increased expression of VEGF and BDNF to a maximum through activating PI3K and ERK1/2 pathways in the hippocampus and frontal cortex in response to transient MCAO. They notably promoted angiogenesis and neurogenesis in vivo. Thus, ICA and MSCs combined treatment may represent a feasible approach for improving the beneficial effects of stem cell therapy for cerebral ischemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available